Menopause hormone therapy: what the FDA label change means

In November 2025 the FDA began removing boxed warnings on heart disease, breast cancer and dementia from menopause hormone therapy. What changed.

By Hydra Editorial

On 10 November 2025 the US Food and Drug Administration began removing boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy. It kept the boxed warning for endometrial cancer on products that contain systemic estrogen alone. The change is a regulatory one, about what appears on the label, and it does not amount to a verdict for every individual.

What did the FDA change, and why?

According to the FDA’s announcement, the decision followed a review of the scientific literature and an expert panel convened in July 2025.

The original warnings trace back to the 2002 Women’s Health Initiative (WHI), which suggested that hormone therapy containing estrogen and progesterone could increase cardiovascular problems, breast cancer and possibly dementia. Harvard Health notes that later analyses raised concerns about that trial: participants were primarily much older than women who typically start hormone therapy, and had underlying risk factors that could skew results. Modern formulations also differ, with lower estrogen doses and skin patches available.

What does the timing hypothesis say, and what is still uncertain?

The label update reflects the “timing hypothesis”: the idea that the balance of benefit and risk depends on when therapy starts. Harvard Health reports that updated FDA guidance will indicate women may see long-term benefits if hormone therapy is started within 10 years of the onset of menopause.

Uncertainty remains in several places:

  • The endometrial cancer warning stays for estrogen-only systemic products.
  • Older patients are a distinct question. A 2026 commentary in the Journal of the American Geriatrics Society is titled “What Geriatricians Should Know”, and looks at how the change applies to that group.
  • The FDA cited percentage benefits for cardiovascular disease, Alzheimer’s disease and fractures from its review. Those figures are contested, so this post does not repeat them.

What is missing from most public discussion is personal context: age, time since menopause, family history and existing conditions all shape how a population finding applies to one woman. That is a decision for a woman and her clinician, and it is the reason population evidence has to be read alongside individual data.

The bottom line

  • On 10 November 2025 the FDA began removing boxed warnings on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy, and kept the endometrial cancer warning for estrogen-alone products.
  • The original warnings rested on the 2002 WHI, whose participants were mostly much older than typical starters; the timing hypothesis points to the first 10 years after menopause onset.
  • The label change describes evidence at a population level; how it applies to an individual depends on personal history and clinical advice.

Frequently asked questions

Did the FDA remove all warnings on menopause hormone therapy?
No. The FDA began removing boxed warnings about cardiovascular disease, breast cancer and probable dementia, but kept the boxed warning for endometrial cancer on products containing only systemic estrogen. Other label information remains.
What is the timing hypothesis for hormone therapy?
It is the idea that risks and benefits depend on when therapy starts. Harvard Health reports updated FDA guidance indicating women may see long-term benefits when therapy begins within 10 years of menopause onset, whereas the original WHI enrolled mostly much older women.

Sources

  1. U.S. Food and Drug Administration, 2025. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA press announcement.
  2. Salamon M, 2025. FDA removes menopause hormone therapy black box warnings. Harvard Women's Health Watch, Harvard Health Publishing.
  3. Hanfling J, 2026. FDA Boxed Warning Removal on Menopause Hormone Therapy: What Geriatricians Should Know. Journal of the American Geriatrics Society.
Hydra Editorial

Hydra's editorial team. We write from primary research and cite every study we rely on, with its year and journal. We quantify claims wherever the evidence allows and state plainly where it does not: where a finding rests on a small or single trial, we say so in the text rather than in a footnote.